Cough & Cold Drug Recalled for Manufacturing Deviations
Ultra Seal Corporation is recalling 225,000 packets of CETAFEN Cough & Cold coated tablets nationwide due to current good manufacturing practice (cGMP) deviations. The recall affects Lot #AK9841 with expiration date 10/2022.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class II and is voluntary and precautionary in nature. No illnesses or injuries are reported in the source text, and the hazard (cGMP deviations) is cited without evidence of actual harm, placing this in the Moderate category per the rubric.
Plain-English summary
Ultra Seal Corporation is recalling 225,000 packets of CETAFEN Cough & Cold Cough & Cold Relief (Acetaminophen 325 mg, Dextromethorphan HBr 15mg, Guaifenesin 200mg, phenylephrine HCl 5mg) coated tablets, sold in 2-count packets and manufactured for HARTHealth in Seattle, WA.
The recall was initiated on January 24, 2022, due to current good manufacturing practice (cGMP) deviations discovered at the manufacturer. This is a voluntary, firm-initiated Class II recall. The affected lot number is AK9841 with an expiration date of October 2022.
The product was distributed nationwide within the United States. Consumers who have purchased this product should stop using it and consult with their healthcare provider if they have questions or concerns about their use of the affected batch.
The recalled product
- Product
- CETAFEN COUGH & COLD COUGH & COLD RELIEF (Acetaminophen 325 mg, Dextromethorphan HBr 15mg, Guaifenesin 200mg, phenylephrine HCl 5mg) Coated tablets, 2-count packets, Manufactured for: HARTHealth Seattle, WA 98124
- Manufacturer
- Ultra Seal Corporation
- Hazard
- cgmp-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: AK9841
- Ex. Date 10/2022
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27